CAR-T CDMOs with Clean FDA Inspection History

· updated as new inspection, certificate, and trial data enters the platform
12
CDMOs tracked
12
Fully scored
9
With FDA records
48
FDA inspections
111
EMA/MHRA GMP certs

CAR-T CDMOs manufacture engineered T-cell products, combining viral-vector transduction, T-cell activation and expansion, and rapid release testing — usually as autologous, per-patient batches on tight vein-to-vein timelines.

Choosing a CAR-T CDMO depends on autologous vs allogeneic experience, in-house vs sourced vector, closed-system processing, and chain-of-identity logistics, alongside a clean regulatory record. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.

FDA inspection outcomes across these CDMOs: 24 NAI (no action), 24 VAI (voluntary action), 0 OAI (official action). Leading inspection & GMP sites: United States (35), Austria (30), Denmark (23), Slovenia (13), Germany (12).

Last updated 2026-10-20. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

Ranked by Signal Score (0–100). Fully evidenced marks a CDMO scored on all four pillars with at least one confirmed clinical program. Partly scored and profile-only CDMOs follow the scored rows. How we score

Showing contract manufacturers only.

# CDMO Signal Score Quality FDA · GMP Last FDA inspection Capacity Programs
1
CR
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
86.3 99.2 9 insp · 11 GMP 2026-05-01 · NAI Limited —
2
MN
Philadelphia, PA · Allendale, NJ · Munich, DE · Yokohama, JP
83.1 99.2 3 insp · 4 GMP 2025-11-25 · NAI Limited —
3
WB2
Shanghai, CN · Wuxi, CN
82.7 99.6 1 insp · 4 GMP 2026-07-03 · VAI — —
4
SC
Prague, Czech Republic
81.6 100.0 0 insp · 5 GMP None on file — —
5
NV
Morris Plains, NJ · Stein, CH
Fully evidenced
Also makes its own products
81.4 97.4 2 insp · 0 GMP 2025-07-11 · VAI Constrained 284 programs
6
CF
Les Ulis, FR
80.3 100.0 0 insp · 4 GMP None on file — —
7
AG
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Hiring · 38 open roles
Fully evidenced
79.9 99.8 4 insp · 27 GMP 2026-05-29 · NAI Available 2 programs
8
RC
Edinburgh, UK · Hopkinton, MA
Hiring · 8 open roles
79.3 96.8 1 insp · 1 GMP 2025-01-21 · VAI Available —
9
MB
Bergisch Gladbach, Germany
Fully evidenced
73.0 100.0 0 insp · 2 GMP None on file — 8 programs
How we score CDMOs →

What to evaluate in a CAR-T CDMO

Vector supply
CAR-T needs a lentiviral or retroviral vector. Confirm whether the CDMO produces vector in-house or coordinates a supplier, and how that affects timelines and cost.
Autologous logistics & turnaround
Autologous CAR-T lives or dies on vein-to-vein time and chain-of-identity. Evaluate scheduling, apheresis handling, and cryo-logistics.
Closed, scalable processing
Closed and automated platforms reduce contamination risk and support parallel patient slots. Ask about cleanroom grade and concurrent-batch capacity.
Regulatory track record
Cross-check FDA 483 history and EMA/MHRA GMP coverage — both shown above and on each profile.

CAR-T CDMOs — Frequently Asked Questions

Who are the top CAR-T CDMOs?
Among CAR-T manufacturers with a fully evidenced Signal Score (all four pillars and at least one ClinicalTrials.gov match), the highest are Bristol Myers Squibb (CGT Mfg), Novartis, City of Hope (T Cell Manufacturing). The table above is the full list. CDMOs cannot pay to change a score.
How many CAR-T CDMOs have FDA inspection records?
CDMO Signal tracks 9 CAR-T CDMOs with FDA inspection records and 111 EMA/MHRA GMP certificates across the group.
What should I look for in a CAR-T CDMO?
Confirm vector supply (in-house or coordinated), autologous logistics and vein-to-vein turnaround, closed-system scalable processing for parallel patients, and a clean FDA and EMA/MHRA record.
Do CAR-T CDMOs make their own viral vectors?
Some produce lentiviral or retroviral vector in-house; others coordinate an external vector CDMO. In-house vector can shorten timelines and de-risk supply. Check each profile's modality coverage above.
Related modalities
Cell Therapy CDMOs Lentiviral Vector CDMOs Gene Editing CDMOs
Other Modalities
AAV Lentiviral Cell Therapy mRNA/LNP Plasmid DNA Biologics Oligo/ASO Adenoviral Gene Editing Exosome Recombinant Proteins ADC Gene Therapy Cell & Gene Therapy Viral Vector